Canaccord maintains a Buy rating and $992 price target on Regeneron, telling investors in a research note that high dose EYLEA should return the franchise to modest growth. The firm, which estimates $59M in high-dose EYLEA revenues during Q3, expects Regeneron will be able to switch roughly 56% of EYLEA revenues to high dose by year-end 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
- Meharry Medical College, partners launch Together for CHANGE initiative
- Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
- Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
- Biotech Alert: Searches spiking for these stocks today
